Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TNDM Stock Forecast 2025-2026
$20.92
Current Price
$1.42B
Market Cap
Buy 8
Hold 14
Sell 1
Wall St Analyst Ratings
Distance to TNDM Price Targets
+162.9%
To High Target of $55.00
-14.0%
To Median Target of $18.00
-33.1%
To Low Target of $14.00
TNDM Price Momentum
-0.4%
1 Week Change
+28.7%
1 Month Change
-30.5%
1 Year Change
-41.9%
Year-to-Date Change
-45.4%
From 52W High of $38.28
+109.6%
From 52W Low of $9.98
📊 TOP ANALYST CALLS
Did TNDM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tandem is one of their latest high-conviction picks.
Latest TNDM Stock Price Targets & Analyst Predictions
Based on our analysis of 30 Wall Street analysts, TNDM has a neutral consensus with a median price target of $18.00 (ranging from $14.00 to $55.00). The overall analyst rating is Buy (7.1/10). Currently trading at $20.92, the median forecast implies a -14.0% downside. This outlook is supported by 8 Buy, 14 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 162.9% upside. Conversely, the most conservative target is provided by Larry Biegelsen at Wells Fargo, suggesting a 33.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TNDM Analyst Ratings
8
Buy
14
Hold
1
Sell
TNDM Price Target Range
Low
$14.00
Average
$18.00
High
$55.00
Current: $20.92
Latest TNDM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TNDM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 2, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $23.00 |
| Nov 10, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $55.00 |
| Nov 10, 2025 | Truist Securities | Richard Newitter | Hold | Reiterates | $17.00 |
| Nov 10, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $17.00 |
| Nov 7, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $14.00 |
| Oct 21, 2025 | Stifel | Jonathan Block | Hold | Reinstates | $15.00 |
| Oct 15, 2025 | Truist Securities | Richard Newitter | Hold | Maintains | $16.00 |
| Oct 7, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $15.00 |
| Sep 29, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $24.00 |
| Sep 8, 2025 | Oppenheimer | Steven Lichtman | Outperform | Maintains | $22.00 |
| Aug 21, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $11.00 |
| Aug 12, 2025 | Citigroup | Joanne Wuensch | Neutral | Upgrade | $10.35 |
| Aug 11, 2025 | Lake Street | Brooks O'Neil | Hold | Downgrade | $12.00 |
| Aug 8, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $51.00 |
| Aug 7, 2025 | UBS | Danielle Antalffy | Neutral | Maintains | $17.00 |
| Aug 7, 2025 | Piper Sandler | Matt O'Brien | Neutral | Downgrade | $14.00 |
| Aug 7, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $25.00 |
| Aug 7, 2025 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $13.00 |
| Aug 7, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $24.00 |
| Jul 9, 2025 | Citigroup | Joanne Wuensch | Sell | Downgrade | $14.00 |
Tandem Diabetes Care Inc. (TNDM) Competitors
The following stocks are similar to Tandem based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TNDM
Tandem Diabetes
mkt cap
1.42B
Tandem Diabetes Care Inc. (TNDM) Financial Data
Tandem Diabetes Care Inc. has a market capitalization of $1.42B with a P/E ratio of -14.2x. The company generates $1.01B in trailing twelve-month revenue with a -20.2% profit margin.
Revenue growth is +2.2% quarter-over-quarter, while maintaining an operating margin of -9.2% and return on equity of -109.7%.
Valuation Metrics
Market Cap
$1.42B
Enterprise Value
$1.55B
P/E Ratio
-14.2x
PEG Ratio
1.2x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+2.2%
Gross Margin
+53.9%
Operating Margin
-9.2%
Net Margin
-20.2%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.5%
Current Ratio
2.4x
Debt/Equity
341.6x
ROE
-109.7%
ROA
-5.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tandem Diabetes Care Inc. (TNDM) Business Model
About Tandem Diabetes Care Inc.
What They Do
Develops innovative insulin delivery systems.
Business Model
The company generates revenue by designing and manufacturing advanced insulin delivery devices, primarily the t:slim X2 insulin pump. This product leverages cutting-edge technology to provide improved diabetes management solutions, targeting both patients and healthcare providers.
Additional Information
Tandem Diabetes Care is dedicated to enhancing patient quality of life through its compact and user-friendly products, which include features like Bluetooth connectivity and compatibility with continuous glucose monitoring systems. The company's focus on innovation positions it as a leader in the diabetes care market, addressing significant medical needs and collaborating with healthcare professionals to improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
2,650
CEO
Mr. John F. Sheridan
Country
United States
IPO Year
2013
Website
www.tandemdiabetes.comTandem Diabetes Care Inc. (TNDM) Latest News & Analysis
Latest News
Quick Summary
Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (NASDAQ: TNDM) for allegedly misleading investors. Affected shareholders may seek compensation with no upfront costs.
Why It Matters
Allegations of misleading information could lead to legal claims against Tandem Diabetes Care, potentially impacting its stock price and shareholder value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care (NASDAQ: TNDM) shareholders over allegations of misleading business information. Investors may seek compensation without upfront fees.
Why It Matters
Allegations of misleading information from Tandem Diabetes Care could lead to significant legal claims, affecting stock value and shareholder rights, potentially impacting investor sentiment and decisions.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (NASDAQ: TNDM) over allegations of misleading business information to investors.
Why It Matters
Allegations of misleading information can lead to legal claims and stock volatility, impacting Tandem Diabetes Care's share price and overall investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (TNDM) for allegedly misleading business information. Affected shareholders may seek compensation with no upfront costs.
Why It Matters
Allegations of misleading information by Tandem Diabetes Care could lead to legal claims, impacting stock value and investor confidence. Potential compensation may attract affected investors.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care (NASDAQ: TNDM) shareholders over allegations of misleading business information. Affected investors may seek compensation without upfront costs.
Why It Matters
Allegations of misleading information from Tandem Diabetes Care could lead to legal claims, impacting stock value and shareholders' potential compensation without upfront costs.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm is investigating potential securities claims against Tandem Diabetes Care (NASDAQ: TNDM) for allegedly misleading business information. Shareholders may seek compensation at no upfront cost.
Why It Matters
Allegations of misleading information from Tandem Diabetes Care could lead to legal claims, impacting stock value and investor confidence, potentially resulting in financial loss or recovery options.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About TNDM Stock
What is Tandem Diabetes Care Inc.'s (TNDM) stock forecast for 2026?
Based on our analysis of 30 Wall Street analysts, Tandem Diabetes Care Inc. (TNDM) has a median price target of $18.00. The highest price target is $55.00 and the lowest is $14.00.
Is TNDM stock a good investment in 2026?
According to current analyst ratings, TNDM has 8 Buy ratings, 14 Hold ratings, and 1 Sell ratings. The stock is currently trading at $20.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TNDM stock?
Wall Street analysts predict TNDM stock could reach $18.00 in the next 12 months. This represents a -14.0% decrease from the current price of $20.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tandem Diabetes Care Inc.'s business model?
The company generates revenue by designing and manufacturing advanced insulin delivery devices, primarily the t:slim X2 insulin pump. This product leverages cutting-edge technology to provide improved diabetes management solutions, targeting both patients and healthcare providers.
What is the highest forecasted price for TNDM Tandem Diabetes Care Inc.?
The highest price target for TNDM is $55.00 from Matt Miksic at Barclays, which represents a 162.9% increase from the current price of $20.92.
What is the lowest forecasted price for TNDM Tandem Diabetes Care Inc.?
The lowest price target for TNDM is $14.00 from Larry Biegelsen at Wells Fargo, which represents a -33.1% decrease from the current price of $20.92.
What is the overall TNDM consensus from analysts for Tandem Diabetes Care Inc.?
The overall analyst consensus for TNDM is neutral. Out of 30 Wall Street analysts, 8 rate it as Buy, 14 as Hold, and 1 as Sell, with a median price target of $18.00.
How accurate are TNDM stock price projections?
Stock price projections, including those for Tandem Diabetes Care Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 2:46 PM UTC